ImmuneOncia Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 12

ImmuneOncia General Information

Description

Operator of a biopharmaceutical company intended to develop immunotherapies by drug development and antibody engineering. The company develops immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors, enabling healthcare professionals to treat various types of cancer.

Contact Information

Website
www.immuneoncia.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 25, Tapsil-ro 35beon-gil
  • Giheung-gu
  • Yongin, Gyeonggi 17084
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 25, Tapsil-ro 35beon-gil
  • Giheung-gu
  • Yongin, Gyeonggi 17084
  • South Korea
+82

ImmuneOncia Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuneOncia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private 02-Nov-2023 Completed Clinical Trials - Phase 2
3. Later Stage VC 16-Jan-2022 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 12-Feb-2019 $40.1M $40.1M Completed Clinical Trials - Phase 2
1. Joint Venture 07-Apr-2016 Completed Startup
To view ImmuneOncia’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ImmuneOncia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to develop immunotherapies by drug development and antibody engineering
Drug Discovery
Yongin, South Korea
15 As of 2024

South San Francisco, CA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmuneOncia Competitors (31)

One of ImmuneOncia’s 31 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
NexImmune Formerly VC-backed Gaithersburg, MD
Immunome Formerly VC-backed Bothell, WA
Hansa Biopharma Corporation Lund, Sweden
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
You’re viewing 5 of 31 competitors. Get the full list »

ImmuneOncia Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 9

    Pending

  • Expiring in next 12 mo

ImmuneOncia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022270543-A1 Bispecific antibody specifically binding to cd47 and pd-l1 Pending 07-May-2021
CA-3219221-A1 Bispecific antibody specifically binding to cd47 and pd-l1 Pending 07-May-2021
US-20240254233-A1 Bispecific antibody specifically binding to cd47 and pd-l1 Pending 07-May-2021
EP-4335872-A1 Bispecific antibody specifically binding to cd47 and pd-l1 Pending 07-May-2021
AU-2021378865-A1 Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof Pending 16-Nov-2020 G01N33/57484
To view ImmuneOncia’s complete patent history, request access »

ImmuneOncia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmuneOncia Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
BNH Investment Venture Capital Minority
Daegyeong Investment Venture Capital Minority
E&Investment Venture Capital Minority
Hanyang Securities Other Minority
K2 Investment Partners Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

ImmuneOncia FAQs

  • When was ImmuneOncia founded?

    ImmuneOncia was founded in 2016.

  • Where is ImmuneOncia headquartered?

    ImmuneOncia is headquartered in Yongin, South Korea.

  • What is the size of ImmuneOncia?

    ImmuneOncia has 15 total employees.

  • What industry is ImmuneOncia in?

    ImmuneOncia’s primary industry is Drug Discovery.

  • Is ImmuneOncia a private or public company?

    ImmuneOncia is a Private company.

  • What is ImmuneOncia’s current revenue?

    The current revenue for ImmuneOncia is .

  • How much funding has ImmuneOncia raised over time?

    ImmuneOncia has raised $60.6M.

  • Who are ImmuneOncia’s investors?

    BNH Investment, Daegyeong Investment, E&Investment, Hanyang Securities, and K2 Investment Partners are 5 of 12 investors who have invested in ImmuneOncia.

  • Who are ImmuneOncia’s competitors?

    CytomX Therapeutics, NexImmune, Immunome, Hansa Biopharma, and Cristal Therapeutics are some of the 31 competitors of ImmuneOncia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »